Information about the mission and objectives of FDA’s Drug Development Tool (DDT) qualification programs.
Similar Posts
Early Alert: Stent and Electrocautery-Enhanced Delivery System Issue from Boston Scientific
Boston Scientific is removing certain stents and delivery systems due to issues with deployment and expansion.Fulijaya Manufacturing SDN. BHD. – 719172 – 01/14/2026
CGMP/Finished Pharmaceuticals/AdulteratedHans Kissle LLC Issues Allergy Alert on Undeclared Wheat (Allergen) in Hans Kissle Red Potato Bliss Salad
Haverhill, MA — Hans Kissle is voluntarily recalling 66 units of Hans Kissle Red Potato Bliss Salad due to undeclared allergen (wheat). People who have an allergy or severe sensitivity to wheat run the risk of serious or life-threatening allergic reaction if they consume these products.President’s Emergency Plan for AIDS Relief (PEPFAR)
Presidential Emergency Plan for AIDS Relief content2023 Meeting Materials, Cardiovascular and Renal Drugs Advisory Committee
This page contains the meeting materials for the Cardiovascular & Renal Drugs Advisory Committee meetings for 2023.FDA Information Session on Generic Drug Research Needs & Opportunities for FY 2026 – 01/21/2026
FDA is hosting a virtual Information Session on Generic Drug Research Needs & Opportunities for fiscal year (FY) 2026 on Wednesday, January 21, 2026.